Wednesday, November 21, 2018

Member Login

Towards an Integrated HTA Framework

    Please find the Press Release here (the content is in Greek)

Internationally, Health Technology Assessment (HTA) is considered the leading approach to govern health systems, manage innovation and inform disinvestment decisions in public and private settings. An effective system requires an integrated environment where interactions can occur at all levels—international, national, regional and local. Each level holds different responsibilities and is characterized by a variety of stakeholders involved both in the provision and use of HTAs for decision-making. International collaborations, national and regional HTA bodies and hospital-based HTA units or functions all contribute to a sustainable healthcare network that requires coordination to improve clinical and organizational processes and patient outcomes.

HTA, however, is now evolving towards an integrated network or “ecosystem” where local needs can be addressed, thanks to both local and global evidence used to support effective and sustainable decisions. This new scenario implies adaptation and changes in methodologies and tools, professional competencies and technical solutions with computational capability for big data analysis.

This new ecosystem is shaped by new and old forms of cooperation with examples of integration now emerging or evolving. For example, the European Network of Health Technology Assessment (EUnetHTA) currently leads HTA collaboration among member states by creating a structured environment in which cooperation in HTA is flourishing. By the end of Joint Action 3 in 2019, it is expected to sustain its own HTA system that is fully integrated within the European regulatory framework for both medicinal products and medical devices.

HTA 2018 Conference
The 2018 HTA Conference in Athens, Greece is aimed at collecting experiences to promote a deeper understanding of the potentials and challenges of different approaches and foster collaboration in HTA and integration between HTA and regulatory systems. On our way to form our New National HTA Body within 2018 and having already established the working criteria of the provisory HTA Committee, we will host enriching discussions around the benefits and challenges of different approaches and draw on European experience to help foster collaboration in HTA. We will explore the value-based paradigm in health care systems and we will define the role of HTA, discuss ways to engage professionals and analyze the balances of multi-stakeholder involvement.

Speakers & Moderators

  • George Giannopoulos, Secretary General, Ministry of Health

  • Magda Chatzikou, PhD, Managing Partner, PharmEcons Easy Access Ltd
  • Panagiotis Georgakopoulos, Vice President, National Organization for the Provision of Healthcare Services (EOPYY)
  • Ilias Giannoglou, Vice President, National Organization for Medicines (EOF)
  • Giorgos Kalamitsis, President of the Hellenic Liver Patient Association "Prometheus», President of the Patient Rights Control Committee
  • Antonis Kontemeniotis, MSc, Purchasing and Supply Directorate, Ministry of Health, Cyprus
  • Dimitrios Kouvelas, Professor and Head of the Dept. of Clinical Pharmacology School of Medicine, Aristotle University of Thessaloniki
  • Despoina Makridaki, President, Pan-Hellenic Association of Hospital Pharmacists (P.E.F.N.I.), Vice President, National Organization for Medicines (EOF)
  • Markos Ollandezos, Scientific Director, Panhellenic Union of Pharmaceutical Companies (PEF)
  • Dimitris Pantazis, CeO, Institute of Pharmaceutical Research & Technology (IFET)
  • Makis Papataxiarchis, President PhRMA Innovation Forum (PIF), Chairman, AMCHAM Pharma Committee
  • Vasileios Pentafragas, Executive Director, Panhellenic Union of Pharmaceutical Industry (PEF)
  • Ioannis Podimatas, Special Advisor to the Secretary General, Ministry of Health
  • Eugena Stamuli, Visiting Research Fellow, University of York, Founder, PharmaEcons UK
  • Filippos Tarantilis, Deputy CeO, Laiko General Hospital of Athens, Member of the Working Committee for the Establishment of an HTA Body in Greece
  • Yiannis Vlontzos, Vice – President, Responsible for HTA and Negotiation, Hellenic Association of Pharmaceutical Companies (SFEE), President and Managing Director of Merck

Key Issues

Key issues to be discussed include:

  • Embracing a Value-Based Paradigm in Health Care Systems
  • Key Issues in the Implementation of HTA & The New Pharmaceutical Policy
  • The New HTA Body & Negotiation Committee in Greece: Principles and the Way Forward

Target Group

  • Healthcare Stakeholders
  • Government representatives
  • Pharmaceutical industry executives ((Market Access, Government Affairs, Health Economics)
  • Public & Private Health services providers
  • Health economists
  • Academics
  • Physicians
  • Patient advocates & patient group representatives

Interview – Video

“The Evolving Approach to Medicines Value Assessment in European Markets”

    Panos Kanavos, PhD, Associate Professor, Deputy Director, LSE Health, Department of Social Policy, London School of Economics

Interview by Nelly Kapsi, Editor –in-Chief, Health Daily

International Speakers

Michael Drummond Mike Drummond is Professor of Health Economics and was Director of the Centre from December 1995 to September 2005. His particular field of interest is in the economic evaluation of health care treatments and programmes.
Dr Panos Kanavos Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health.
Katarzyna Kolasa, PhD Katarzyna Kolasa has more than 16 years of working experience in the healthcare sector, with 10 years with the pharmaceutical and medical devices industry and six with the public payer.
Vladimir Zah Vladimir Zah, PhD(c), brings 20+ years of Health Economics technology and business experience. Since 2000, in various roles as Health Economist, Project Manager and Chief Investigator, Vlad has implemented more than 170 health economic models and assessments in the phase 2, 3 and 4 settings, across various disease areas for top 20 global pharmaceutical companies; work supported with over 50 publications.

© 2018 Boussias Communications, all rights reserved., T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team